Browse the evidence

Tirzepatide demonstrates potential kidney-protective effects by slowing the decline in eGFR and reducing urinary albumin-to-creatinine ratio (UACR) compared to insulin glargine.

While not yet a primary indication, early data suggests tirzepatide may help protect kidney function in T2D patients, potentially slowing kidney disease progression compared to insulin. This benefit is observed even in patients already taking other kidney-protective medications.

SGLT2 inhibitors reduce epicardial fat volume independently of significant weight loss, suggesting a direct lipolytic effect on epicardial tissue.

SGLT2 inhibitors are a key pharmacological option for HFpEF patients. They reduce epicardial fat directly, which may improve heart mechanics and reduce hospitalizations. Discuss with your doctor if SGLT2 inhibitors are appropriate for your condition.

Patients with active psychiatric disorders, particularly depression, may exhibit lower response rates to semaglutide and are at risk of weight gain during treatment.

If you have active depression or other psychiatric conditions, monitor your weight closely when starting semaglutide, as some patients may not lose weight or may even gain weight.

BGM0504, a GLP-1R/GIPR dual agonist with optimized acylation, demonstrates superior glycemic control, weight loss, and liver health improvements compared to Tirzepatide in diabetic and NASH mouse models.

BGM0504 is an experimental dual-agonist peptide designed to treat diabetes and obesity more effectively than existing drugs like Tirzepatide. In animal studies, it lowered blood sugar and body weight with fewer side effects on liver health. It is not yet available for human use.

A high-carbohydrate diet (CHORD) commonly prescribed for CPTII deficiency may be detrimental long-term by causing hyperinsulinemia, which inhibits CPT enzymes and diverts fatty acids to storage, potentially worsening insulin resistance and metabolic health.

Current advice to eat a very high-carb, low-fat diet might be hurting your long-term health. Try shifting to a moderate-carb diet (50-55% of calories) with higher protein (25-30%). This helps lower insulin levels, which may improve your body's ability to manage fatty acids and reduces the risk of insulin resistance.

Bariatric surgery (Roux-en-Y gastric bypass) significantly reduces circulating microvesicles (MVs) of monocyte and endothelial origin, specifically those expressing the CD36 scavenger receptor, within three months post-surgery.

For patients undergoing Roux-en-Y gastric bypass, significant reductions in inflammatory vascular markers (specifically CD36-bearing microvesicles from monocytes and endothelial cells) occur within just three months. This suggests that the surgery rapidly alleviates endothelial stress and low-grade inflammation associated with obesity, potentially reducing long-term cardiovascular risk beyond just weight loss.

Non-surgical weight management programs (WMPs) for adults with severe obesity (BMI ≥ 35 kg/m2) lack a clear consensus on cost-effectiveness, largely due to short-term study durations and heterogeneous definitions of usual care.

For individuals with severe obesity (BMI ≥ 35), non-surgical weight management programs exist but their cost-effectiveness is not clearly established. Most studies are short-term and do not capture long-term health outcomes. It is important to consult with healthcare providers to understand the potential benefits and costs of various non-surgical options, including lifestyle changes, VLCDs, and pharmacotherapy, as the evidence is heterogeneous.

Quercetin supplementation has no significant effect on Interleukin-6 (IL-6) concentrations after exercise.

Do not expect quercetin to significantly lower IL-6 levels post-exercise based on current meta-analytic data.

Adherence to an ultra low-fat diet (ULF) leads to a compensatory increase in refined grain intake, which may undermine the cardioprotective potential of fat restriction.

If you choose a low-fat diet, be aware that your body may crave carbohydrates. You must actively replace the calories from fat with vegetables and whole foods, not refined grains or sugars. If you find yourself eating more bread or pasta to feel full, your heart health benefits may be negated by the increased refined carbohydrate intake.

Soluble GPNMB (sGPNMB) promotes lipogenesis in white adipose tissue by activating SREBP1c via CD44 binding, thereby acting as a risk factor for obesity progression.

This research highlights that obesity involves complex signaling where soluble proteins released by fat cells can drive further fat storage. While not a direct lifestyle intervention, understanding this mechanism underscores why reducing adiposity (via caloric deficit and exercise) is crucial, as it reduces the source of these pro-lipogenic signals.

Membrane-bound GPNMB on anti-inflammatory macrophages reduces oxidative stress, lipid accumulation, and fibrosis in the liver by interacting with calnexin on Kupffer and stellate cells.

This finding suggests that maintaining healthy macrophage function in fat tissue may have downstream benefits for liver health, potentially reducing the risk of fatty liver disease associated with obesity.

Obesogenic food environments disproportionately increase obesity risk for women compared to men due to biological factors (hormonal modulation of taste/storage), gendered marketing targeting women, and structural burdens (unpaid labor/food security) that limit healthy food access.

Recognize that obesity is not just a personal failure but a result of an environment designed to promote weight gain, which affects women differently due to biological and social factors. Focus on structural changes (policy, food environment) rather than just individual willpower. For women, be aware that marketing and household responsibilities may create unique barriers to healthy eating that require specific, gender-responsive solutions.

Lower-body fat (LBF) is associated with more favorable left ventricular contractility, potentially acting as a metabolic sink that protects against ectopic fat deposition.

While reducing visceral fat is critical, having some lower-body fat may offer metabolic protection by storing excess lipids safely. However, this benefit is overshadowed by high visceral fat.

Semaglutide use is associated with a significantly higher reporting odds ratio for vision impairment and retinopathy compared to other GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, metformin, phentermine, and orlistat.

If you are taking semaglutide, be aware that there is a statistical signal for increased vision impairment reports in post-market data compared to other diabetes or weight loss drugs. This does not mean everyone will experience this, but it warrants vigilance. Ensure you have regular ophthalmological check-ups, especially if you have pre-existing diabetic retinopathy or rapid glycemic changes, and report any visual disturbances to your provider immediately.

Intravenous amino acid infusion improves muscle protein synthesis and reduces perioperative blood loss in total joint arthroplasty patients.

If your surgical team recommends intravenous amino acids during your joint replacement, it may help preserve muscle protein and reduce blood loss. This is a specific medical intervention that complements your surgery, not a substitute for post-operative nutrition.

Ghrelin levels, specifically the ratio of unacylated to acylated ghrelin, are altered in NAFLD patients, with decreased plasma unacylated/acylated ghrelin ratio and increased hypothalamic acylated ghrelin expression correlating with insulin resistance and NAFLD severity.

Research indicates that ghrelin signaling is disrupted in NAFLD, with specific changes in ghrelin ratios correlating with insulin resistance. While ghrelin antagonists like pegvisomant are being studied, they are not yet established treatments. Current clinical focus remains on GLP-1 agonists for managing NAFLD.

Bariatric surgery (BS) improves NAFLD outcomes by altering bile acid bioavailability, which activates the Fxr-Glp-1 axis, improves glucose homeostasis, and reestablishes normal ghrelin responses.

For obese patients with NAFLD, bariatric surgery is a viable treatment option that not only reduces weight but also improves liver health through hormonal changes. It reestablishes normal ghrelin responses and activates pathways that improve glucose homeostasis. If you are considering surgery, discuss how it might specifically benefit your liver health beyond weight loss.

GLP-1 receptor agonists protect endothelial function by reducing oxidative stress, inhibiting inflammation, and promoting nitric oxide (NO) production.

This node explains the biological mechanism: GLP-1 drugs help keep blood vessel linings healthy by reducing inflammation and oxidative stress, which prevents the buildup of plaque. This is a key reason why these drugs protect the heart.

GLP-1 receptor agonists reduce foam cell formation and promote anti-inflammatory M2 macrophage polarization, thereby stabilizing atherosclerotic plaques.

GLP-1 drugs help stabilize existing plaque in arteries by changing how immune cells (macrophages) behave. They encourage these cells to become 'anti-inflammatory' (M2 phenotype) and help remove excess cholesterol, which reduces the risk of plaque rupture and heart attack.

DPP-4 inhibitors, specifically sitagliptin, are significantly associated with an increased risk of biliary disorders, including gallbladder-related diseases and biliary malignant tumors.

If you are taking a DPP-4 inhibitor (like sitagliptin), be aware of symptoms like right-sided abdominal pain, nausea, or fever, which could indicate gallbladder issues. Discuss these risks with your doctor, especially if you have been on the medication for a long time.

Specific GLP-1 receptor agonists, semaglutide and liraglutide, are significantly associated with an increased risk of biliary disorders, including gallbladder-related diseases and biliary malignant tumors.

If you are taking Semaglutide or Liraglutide, watch for signs of gallbladder problems, such as pain in the upper right abdomen, nausea, or fever. These drugs can slow down your gallbladder, so report any such symptoms to your doctor promptly.

Sleeve Gastrectomy (SG) in adolescents results in a blunted reduction in Resting Energy Expenditure (REE) relative to total body weight loss compared to lifestyle-induced weight loss, potentially aiding long-term weight maintenance.

For adolescents with severe obesity, Sleeve Gastrectomy appears to preserve metabolic rate better than lifestyle-induced weight loss, which typically causes a sharp drop in energy expenditure. This 'blunting' of metabolic adaptation may help explain why surgery often leads to more sustained weight loss compared to diet and exercise alone.

Genetic variants in GLP1R that increase weight loss efficacy are also associated with an increased risk of nausea and vomiting, suggesting a link between efficacy and side effects.

Research suggests that the same genetic factors that help you lose more weight with GLP-1 medications may also make you more prone to nausea and vomiting. This doesn't mean you must suffer, but it highlights why side effects vary so much between individuals. If you are struggling with severe side effects, it might be worth discussing with your doctor whether a different medication or dose adjustment could help, as your genetics might be driving both your response and your side effects.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly, liraglutide 3.0 mg daily) cause modest bone mineral density (BMD) reduction and increase bone turnover markers (favoring resorption) in people living with obesity, mirroring the effects of calorie restriction.

If you are taking GLP-1 agonists like Wegovy or Saxenda for weight loss, expect a small decrease in bone density (around 2-3%) over a year, similar to losing weight through diet alone. This is not unique to the drug but to the weight loss itself. To protect your bones, prioritize resistance training and ensure you are getting enough calcium and Vitamin D. The benefit of weight loss generally outweighs this modest skeletal risk, but monitoring is advised.